Stakeholder collaboration can aid REMS implementation.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2010 AND VI 45 AND IP 5
Results: 27
1
2
'At-risk' generic launches can be unpredictable.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
3
P&T committees tasked with ensuring safety and quality.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
4
FDA not ready to declare link between oral bisphosphonates and atypical subtrochanteric femur fractures.
- Published in:
- 2010
- Publication type:
- Journal Article
5
Meta-analysis finds antidiabetic drugs lower glucose similarly when added to metformin in type 2 diabetes mellitus.
- Published in:
- 2010
- Publication type:
- Journal Article
6
FDA actions in brief.
- Published in:
- 2010
- Publication type:
- Journal Article
7
First-time generic approvals.
- Published in:
- 2010
- Publication type:
- Journal Article
8
FDA panel recommends continued use of Rotarix and RotaTeq vaccines despite viral DNA contamination.
- Published in:
- 2010
- Publication type:
- Journal Article
9
Guideline-specific management of atrial fibrillation.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
10
Ticagrelor: an oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
11
Epilepsy/seizure disorders.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 170
- Publication type:
- Article
12
Health reform expands drug coverage, supports outcomes research.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 168
- By:
- Publication type:
- Article
13
FDA panel recommends continued use of Rotarix and RotaTeq vaccines despite viral DNA contamination.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 167
- Publication type:
- Article
14
FDA approves a more tamper-resistant formulation of OxyContin.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 166
- Publication type:
- Article
15
FDA not ready to declare link between oral bisphosphonates and atypical subtrochanteric femur fractures.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 166
- Publication type:
- Article
16
"At-risk" generic launches can be unpredictable.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 165
- By:
- Publication type:
- Article
17
Stakeholder collaboration can aid REMS implementation.
- Published in:
- 2010
- By:
- Publication type:
- Proceeding
18
Guideline-specific management of atrial fibrillation.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 156
- By:
- Publication type:
- Article
19
Ticagrelor: An oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 148
- By:
- Publication type:
- Article
20
5-alpha reductase inhibitors reduce prostate cancer risk, but not all experts are ready to support their chemopreventive role.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 146
- Publication type:
- Article
21
Pipeline preview.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 144
- Publication type:
- Article
22
First-time generic approvals.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 145
- Publication type:
- Article
23
FDA actions in brief.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 145
- Publication type:
- Article
24
Silenor.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 144
- Publication type:
- Article
25
Xifaxan.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 144
- Publication type:
- Article
26
Meta-analysis finds antidiabetic drugs lower glucose similarly when added to metformin in type 2 diabetes mellitus.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 146
- Publication type:
- Article
27
P&T committees tasked with ensuring safety and quality.
- Published in:
- Formulary, 2010, v. 45, n. 5, p. 143
- By:
- Publication type:
- Article